Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 2/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223037 | 0.81 | TSHR (0.38) | RXRAGRIN1GRIN2B | |
| SCHEMBL6918342 | 0.80 | MAPK8 (0.45) | RXRAGRIN1GRIN2BMAPK8 | |
| SCHEMBL22576627 | 0.80 | SMN1; SMN2 (0.41) | RXRAGRIN1GRIN2BMAPK8 | |
| SCHEMBL4582943 | 0.79 | RECQL (0.37) | RXRAGRIN1GRIN2BRXRBMAPK8 | |
| SCHEMBL7029492 | 0.79 | POLB (0.42) | RXRAGRIN1GRIN2BMAPK8SSTR5 | |
| SCHEMBL12678476 | 0.76 | RXRA (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL22799650 | 0.75 | KDM4E (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL18689558 | 0.75 | RXRA (0.37) | RXRARXRBRXRG | |
| SCHEMBL8958798 | 0.75 | SCN9A (0.33) | RXRAGRIN1GRIN2BSCN9A | |
| SCHEMBL937563 | 0.74 | NUDT1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-13 | — | — | US | disclosed |
| EP-2678317-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-01-01 | — | — | EP | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2012114268-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-30 | — | — | WO | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6369040-B1 | INCORPORATING A COMPLEMENTARY SEQUENCES FOR HERPES, PAPILLOMA AND OTHER VIRUSES | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6060592-A | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-5459243-A | Apparatus and processes for the large scale generation and transfer of diazomethane | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995024185-A1 | NOVEL PYRIMIDINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | RXRA 3172/4885GRIN1 1912/4885GRIN2B 3632/4885 |
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX3, P2RX7, P2RX1 | RXRA 577/4885GRIN1 704/4885GRIN2B 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.